Crescita Therapeutics Announces the Results of its Annual General and Special Meeting of Shareholders
May 12 2021 - 06:30AM
Business Wire
Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF)
(“Crescita” or the “Company”), a growth-oriented, innovation-driven
Canadian commercial dermatology company, today announced the voting
results from its 2021 Annual General and Special Meeting of
Shareholders held at its corporate headquarters in Laval, Québec.
The detailed results of the votes received by proxy are as
follows:
Election of Directors
Director Nominees
NUMBER OF SHARES
PERCENTAGE OF VOTES
CAST
FOR
WITHHELD
FOR
WITHHELD
Daniel N. Chicoine
2,549,254
383,576
86.9
%
13.1
%
David A. Copeland
2,829,180
103,650
96.5
%
3.5
%
Anthony E. Dobranowski
2,779,033
153,797
94.8
%
5.2
%
John C. London
2,830,264
102,566
96.5
%
3.5
%
Thomas Schlader
2,777,856
154,974
94.7
%
5.3
%
Appointment of External Auditors
Outcome
NUMBER OF SHARES
PERCENTAGE OF VOTES
CAST
FOR
WITHHELD
FOR
WITHHELD
Ernst & Young LLP
reappointed
3,240,957
394,460
89.1
%
10.9
%
Approval of the Continuation of Crescita’s Share Incentive
Plan
Outcome
NUMBER OF SHARES
PERCENTAGE OF VOTES
CAST
FOR
WITHHELD
FOR
WITHHELD
Share Incentive Plan approved
2,485,187
447,643
84.7
%
15.3
%
About Crescita Therapeutics Inc.
Crescita (TSX: CTX and OTC US: CRRTF) is a growth-oriented,
innovation-driven Canadian commercial dermatology company with
in-house research and development (“R&D”) and manufacturing
capabilities. The Company offers a portfolio of high-quality,
science-based non-prescription skincare products and early to
commercial stage prescription products. In addition, we own
multiple proprietary transdermal delivery platforms that support
the development of patented formulations to facilitate the delivery
of active ingredients into or through the skin.
Our non-prescription portfolio includes a wide variety of
premium quality dermocosmetic products which include facial creams,
cleansers, exfoliants, masks, serums and suncare, that each serve a
different and personalized consumer need. The portfolio is designed
to address preventive care to combating the first signs of aging,
as well as all primary aesthetic skin concerns. Our dermocosmetic
products address two sub-sets of the skincare market: aesthetics
and medical aesthetics. In Canada, our national sales force calls
on aesthetic practitioners and medical aesthetic clinics and
medispas using a business to business to consumer model. LDR
products can also be purchased through our online platform. Our
skincare brands are also sold in certain Asian markets, such as
Malaysia, South Korea and China through international distributors
and through various e-commerce platforms.
Crescita’s portfolio also includes Pliaglis, our lead
prescription product, that utilizes our proprietary phase-changing
topical cream Peel technology. Pliaglis is a topical local
anesthetic cream that provides safe and effective local dermal
analgesia on intact skin prior to superficial dermatological
procedures. The product is currently approved in over 25 different
countries, is sold by commercial partners in the U.S., Italy, Spain
and Brazil, and was most recently licensed to partners in Austria,
Mexico and China. We also market Pliaglis in the Canadian
physician-dispensed skincare market through our own sales
force.
Our expertise in topical product formulation and development can
be leveraged in combination with our patented transdermal delivery
technologies to develop and manufacture creams, liquids, gels,
ointments and serums under our contract development and
manufacturing organization infrastructure. We run our operations
from our head office located in the heart of the Biotech City in
Laval, Québec, where we also manufacture the majority of our
non-prescription skincare products in our 50,000 square-foot
facility.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210512005509/en/
FOR MORE INFORMATION: Investor Relations Linda Kisa, CPA,
CA
Email: ir@crescitatx.com
Crescita Therapeutics (TSX:CTX)
Historical Stock Chart
From Feb 2024 to Mar 2024
Crescita Therapeutics (TSX:CTX)
Historical Stock Chart
From Mar 2023 to Mar 2024